Bangkok: With interest rate wars still unstable, electricity has become a new battleground, and the medical field holds hope in the fight against pancreatic cancer. While the end of the month brings relief to salaried workers with money in their pockets, the following weeks may become more worrisome. Recent figures from the National Economic and Social Development Council (NESDC) on Thailand's social situation in the second quarter indicate that household debt remains relatively high at around 85% of GDP, a significant drop from its previous rapid rise to over ninety percent. Amidst tighter financial conditions and easier access to credit, debt relief has become increasingly difficult. Challenging factors from global monetary policy and domestic infrastructure are becoming unavoidable for all Thais.
According to Thai News Agency, global interest rate trends have impacted the Thai baht. At a recent meeting in Jackson Hole, Kevin Warsh, the new Federal Reserve Governor, delivered a lengthy 30-minute speech, longer than usual. The main points were his affirmation of his commitment to seriously control inflation and bring it back to the 2% target, refusing to accept any inflation figures higher than that. He also signaled a move away from forward guidance, allowing the market to assess the situation on its own. This signal caused the yield on 2-year US Treasury bonds to surge from 4.24% to 4.36%, and the yield on 10-year bonds to climb to 4.73%. Futures markets estimate a 56-57% chance that the Fed will raise interest rates at its September meeting to 3.75% to 4.00%, and potentially raise them two more times to exceed 4% this year. This concern is directly reflected in the volatility of the Thai baht, which weakened rapidly from 32.64 baht per dollar on Tuesday to 33.16 baht per dollar in less than a week.
The Power Development Plan (PDP) presents a major challenge to support "data centers" and the Net Zero goal. Thailand is preparing to hold a public consultation on the draft PDP, a matter of utmost urgency given the influx of artificial intelligence (AI) and investment in data centers. These businesses require enormous amounts of electricity 24/7 and also demand clean energy to align with Thailand's goal of achieving net-zero greenhouse gas emissions by 2050. Currently, Thailand has a power generation capacity of approximately 56 gigawatts, with about two-thirds (38 gigawatts) coming from natural gas. Solar power accounts for only 4 gigawatts. Under the new plan, it is estimated that the country needs to increase its power generation capacity by 200 gigawatts, aiming to push the proportion of solar energy to 60% by 2050.
However, a major problem with solar cells is that their actual electricity generation efficiency averages less than 20% (approximately 17-18%) of total capacity because they only generate electricity during the daytime when there is sunlight. Therefore, Thailand faces enormous investment costs in two key areas: Energy storage systems (battery backup) need to be improved from the current 1-2 gigawatts to 50-60 gigawatts, or possibly even up to almost 100 gigawatts, to maintain the system's power supply coverage. Additionally, a Smart Grid for distributing and purchasing electricity back from households is essential. Dr. Supavud estimates that the cost required for this energy transition to support data centers and the Net Zero goal could reach 5-7 trillion baht, far short of the initial 200 billion baht transition budget. More than half, or two-thirds, of this amount must be invested in solar power and batteries, and at least another 2 trillion baht for smart grid systems. Furthermore, in an era of declining T hai population and lower birth rates, if AI increasingly replaces humans, Thailand's competitiveness will be judged on the efficiency and cost-effectiveness of these energy sources.
In positive news, a new hope has emerged in the fight against pancreatic cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the drug "Darasolasis" (brand name "Rasonix") from Revolution Medicines. This drug was developed to treat pancreatic cancer, known as one of the most difficult cancers to treat in the world. Most patients have less than a 10% chance of survival and often die within 2-3 months of diagnosis. This drug works by targeting "Ras protein," a protein that, when mutated, stimulates cancer growth. Studies have shown that patients receiving this drug have an average survival time of 13.2 months, compared to only 6.7 months for those who did not receive the drug (saving over 6 months of life). It also delays cancer recurrence for 7.2 months, compared to 3.6 months in the original group. This represents a historic achievement in medicine, as there has been no such treatment for over 20-30 years. However, a major obstacle is the cost. This medication is extremely expensive, costing a staggering $477,000 per year (or approximately 16-17 million baht per year), which would be a heavy financial burden without a health insurance system or assistance programs to help cover this expense.